Evidence map›Paper›PMID 34099491›Full record

ArticleCancer research2021

Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival.

Riaz Gillani, Bo Kyung A Seong, Jett Crowdis, Jake R Conway, Neekesh V Dharia, Saif Alimohamed, Brian J Haas, Kyuho Han, Jihye Park, Felix Dietlein and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

Riaz GillaniDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-8643-2725
Bo Kyung A SeongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-1398-6230
Jett CrowdisBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Jake R ConwayBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Neekesh V DhariaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-5048-067X
Saif AlimohamedWake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina.
Brian J HaasBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Kyuho HanDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-4259-8736
Jihye ParkBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-4451-2046
Felix DietleinBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Meng Xiao HeBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Alma ImamovicBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Clement MaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Michael C BassikDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Jesse S BoehmBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-6795-6336
Francisca VazquezBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-2857-4685
Alexander GusevDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
David LiuBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0003-0346-5033
Katherine A JanewayDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
James M McFarlandBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0001-9978-480X
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Eliezer M Van AllenBroad Institute of Harvard and MIT, Cambridge, Massachusetts. eliezerm_vanallen@dfci.harvard.edu.
Broad Institute · USBoston Children's Hospital · USDana-Farber Cancer Institute · USHarvard University · USStanford Health Care · USStanford University · USWake Forest University · US

Funding

Training Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8M
Research Training in Pediatric OncologyT32CA136432 · NCI · DANA-FARBER CANCER INST · PI SCOTT A ARMSTRONG · 2009 to 2026
$7.9M
Trinity: Transcriptome assembly for genetic and functional analysis of cancerU24CA180922 · NCI · BROAD INSTITUTE, INC. · PI HAAS, BRIAN · 2013 to 2022
$7.5M
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerR35CA210030 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2016 to 2022
$7.3M
Molecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2M
Molecular Origins and Evolution to Chemoresistance in Germ Cell TumorsR37CA222574 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2024
$3.2M
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
Open Software and Resource Development Leveraging Next-gen Sequencing Data to Facilitate Computational Analysis of Cancer BiologyR50CA211461 · NCI · BROAD INSTITUTE, INC. · PI HAAS, BRIAN · 2016 to 2020
$1.7M
NCI NIH HHS R01 CA227388NCI NIH HHS R35 CA210030NCI NIH HHS R37 CA222574NCI NIH HHS R50 CA211461NCI NIH HHS T32 CA136432NCI NIH HHS U01 CA233100NCI NIH HHS U24 CA180922NHGRI NIH HHS T32 HG002295
6 · The paper itself

Abstract

Gene fusions frequently result from rearrangements in cancer genomes. In many instances, gene fusions play an important role in oncogenesis; in other instances, they are thought to be passenger events. Although regulatory element rearrangements and copy number alterations resulting from these structural variants are known to lead to transcriptional dysregulation across cancers, the extent to which these events result in functional dependencies with an impact on cancer cell survival is variable. Here we used CRISPR-Cas9 dependency screens to evaluate the fitness impact of 3,277 fusions across 645 cell lines from the Cancer Dependency Map. We found that 35% of cell lines harbored either a fusion partner dependency or a collateral dependency on a gene within the same topologically associating domain as a fusion partner. Fusion-associated dependencies revealed numerous novel oncogenic drivers and clinically translatable alterations. Broadly, fusions can result in partner and collateral dependencies that have biological and clinical relevance across cancer types. SIGNIFICANCE: This study provides insights into how fusions contribute to fitness in different cancer contexts beyond partner-gene activation events, identifying partner and collateral dependencies that may have direct implications for clinical care.

Indexed as

Cell SurvivalGene FusionHumansNeoplasms

Identifiers

PMID34099491
PMCPMC8338889
OpenAlexW3172710074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.